Oct. 23 at 6:09 PM
$CMMB Chemomab’s focus on PSC taps into a niche market with premium pricing potential and broadens into other fibrotic diseases. Chemomab Therapeutics Ltd. is developing nebokitug (CM-101), a first-in-class monoclonal antibody targeting CCL24, a protein implicated in fibro-inflammatory diseases. The significance of this product, particularly for primary sclerosing cholangitis (PSC), stems from its focus on a rare, underserved disease with high unmet medical needs. Nebokitug’s unique mechanism could be a competitive edge. It lies in its potential to address PSC, a rare disease with no approved treatments, high morbidity, and significant regulatory incentives.
